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Abstract
Introduction: The most common site for the metastasis of papillary carcinoma of the thyroid
(PTC) is regional lymph nodes. Ultrasound (US) imaging may identify abnormal appearing lymph
nodes, suspicious for PTC recurrence. Although fine needle aspiration biopsy (FNAB) of abnormal
lymph nodes is often diagnostic of recurrence, small or cystic lymph nodes may be non-diagnostic
due to lack of tumor cells. The measurement of thyroglobulin (TG) levels in FNAB specimens from
lymph nodes suspicious for recurrent PTC can serve as an adjunct to the cytologic diagnosis.
Materials and methods: 115 abnormal appearing lymph nodes were aspirated under ultrasound
guidance in 89 patients with history of thyroid carcinoma. In addition to obtaining material for
cytologic interpretation, an additional aspirate was obtained by FNAB and rinsed in 1 ml of normal
saline for TG level measurements.
Results: The cytologic diagnoses included: 35 (30%) reactive lymph node, no tumor seen (NTS),
39 (34%) PTC, 23 (20%) inadequate for evaluation due to lack of lymphoid or epithelial cells (NDX)
15 (13%) atypical/suspicious for PTC, and 3 (3%) other (e.g. paraganglioma, poorly differentiated
carcinoma and carcinoma not otherwise specified). TG levels were markedly elevated (median 312
ng/ml; normal < 10 ng/ml) in 28 (72%) cases of PTC lymph node recurrence identified on cytology.
TG measurements were also elevated in 5 lymph nodes classified as NTS and 4 NDX on cytology
which resulted in 5 and 3 carcinoma diagnoses respectively on histological follow-up. Of the 9
atypical/suspicious cases with elevated TG levels all resulted in carcinoma diagnoses on follow-up.
Conclusion: The measurement of TG in FNAB specimens from lymph node in patients with
history of PTC is useful in detecting recurrent disease, especially in cases when the specimen is
known to be or likely to be inadequate for cytologic evaluation.
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Introduction
Papillary thyroid carcinoma (PTC) is the most common
malignant tumor of thyroid. Though in majority of cases
PTC behaves in an indolent fashion, it can spread through
lymphatics within the thyroid gland (multi-focal disease)
and metastasize to the cervical lymph nodes [1-3]. In
patients with a previous diagnosis of PTC, the clinical or
radiologic detection of enlarged cervical lymph nodes
raises the suspicion of recurrent disease [3,4].
Fine needle aspiration biopsy (FNAB) can effectively diag-
nose PTC because its diagnosis is based upon the demon-
stration of classic nuclear features [5,6]. It has been shown
that FNAB is effective alone or in conjunction with ultra-
sound guidance in the diagnosis of metastasis from PTC
to the cervical lymph nodes [7,8]. However, in some
instances the metastatic deposits of PTC in the lymph
nodes may undergo degeneration and cystic change [9-
11]. In such instances the FNAB of lymph nodes even with
ultrasound guidance may only show colloid type mate-
rial, cellular debris and macrophages without any identi-
fiable tumor cells. These specimens are usually classified
as "non-diagnostic or unsatisfactory for evaluation
[9,11,12]."
Measurement of thyroglobulin (TG) in the FNAB needle
rinse from the cervical lymph nodes has been employed
for detecting recurrent thyroid cancer in patients who
have undergone total thyroidectomy and 131I therapy for
differentiated thyroid cancer [11-19].
In this study we evaluated the role of FNAB-TG in detect-
ing lymph node recurrence in patients with previous his-
tory of thyroid carcinoma at our institution.
Materials and Methods
Patients
The cohort included 115 FNAB specimens in eighty-nine
patients (21 male, 68 female; ranging in age 14–83 years
(mean: 46.7 years). Seventy-four patients had a history of
PTC, two had a history of follicular carcinoma with asso-
ciated papillary microcarcinoma, one had Hurthle cell
carcinoma with associated papillary microcarcinoma and
one had history of poorly differentiated carcinoma
(PDCA) arising in association with follicular variant of
papillary thyroid carcinoma (FVPTC). Surgical pathology
slides were not available for review in eleven patients with
history of PTC. All patients with previous diagnoses of
PTC had been treated by total or partial thyroidectomy
with subsequent completion thyroidectomy and 131I abla-
tion. Of the 77 PTC (including 3 papillary microcarci-
noma), 53 were classified as classic variant, 10 as FVPTC,
12 as tall cell variant of papillary thyroid carcinoma (PTC-
TCV), and 2 as diffuse sclerosis variant (PTC-DSV). The
tumor size of the cases of PTC was available in 53 cases
and ranged from 0.4–7.8 cm (mean 2.07 cm); vascular
invasion was seen in 29; extra-thyroidal extension in 36
and multi-focal disease in 41 patients. Lymph node
metastases were present at the time of initial surgery in 64
patients.
FNAB
All lymph nodes were initially localized and measured
(size range 0.7–3.7 cm) using a high-frequency linear 10-
5 MHz transducer and an ATL 3000 ultrasound scanner
(Advanced Technology Laboratories, Bothell, WA) (Fig 1).
Ultrasound-guided FNAB was performed using a 25-
gauge, 1.5 inch needle and an 8-5 MHz curvilinear trans-
ducer using real-time, free hand technique.
The first FNAB pass was evaluated on-site by the
cytopathologist; it was divided between fresh smears and
Normosol® for Millipore-filter® preparations. Half of the
fresh smears were stained with Diff-Quik for immediate
on-site evaluation and the others were placed in 95%
alcohol for Papanicolaou staining. The second FNAB pass
was washed in Normosol and the entire wash was submit-
ted for TG assay.
TG Assay
TG levels in the lymph node FNAB specimens were meas-
ured by employing Nicohls Chemiluminescence Thy-
roglobulin-TG assay (Nicohls Institute Diagnostics, San
Clemente, CA) with an analytical sensitivity of ≤ 0.04 ng/
ml and functional sensitivity of ≤ 0.3 ng/ml.
Results
FNAB Findings
Metastatic PTC was diagnosed in 39 (34%) specimens (Fig
2). Fifteen aspirates (13%) were diagnosed as suspicious
for PTC; these included 9 cases showing colloid and mac-
rophages and no viable tumor cells present and 6 cases
with atypical cell present suspicious for PTC. Thirty-five
(30%) cases were diagnosed as reactive lymphoid tissue
only no tumor seen, 23(20%) were classified as inade-
quate for evaluation due to lack of any lymphoid or epi-
thelial cells, and in 3 (3%) cases the diagnosis included
paraganglioma 1, PDCA 1 and carcinoma not further
specified 1 case.
FNAB-TG Levels
FNAB-TG levels in the 39 cases diagnosed as metastatic
PTC by cytology ranged from < 0.3–195200 ng/ml
(median 312 ng/ml, normal < 10 ng/ml). In 28 cases
(72%) TG levels were ≥ 10 ng/ml (mean 17267.75); his-
topathologic confirmation of metastatic PTC was availa-
ble in 25 cases; no histologic follow-up was available in
the remaining 3 cases. Of the eleven cases (28%) with TG
levels < 10 ng/ml, 7 cases were diagnosed as PTC-TCV, 3
as classic-PTC and one as metastatic well-differentiatedCytoJournal 2008, 5:1 http://www.cytojournal.com/content/5/1/1
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follicular derived carcinoma on histological follow-up. In
this group one case of metastasis from PTC had a previous
diagnosis of follicular carcinoma with a 0.7 cm focus of
papillary microcarcinoma.
In 35 cases diagnosed as no tumor seen (NTS) on cytology
(n = 35) FNAB-TG levels ranged from < 0.15–411900 ng/
ml (median 0.3 ng/ml). In this group 30 cases (86%) had
TG levels < 10 ng/ml. All 5 cases diagnosed as NTS with
TG levels ≥ 10 ng/ml underwent surgery and on histolog-
ical follow-up 3 were diagnosed as classic PTC, and 2 as
FVPTC.
In the 23 cases diagnosed as non-diagnostic/inadequate
due to lack of lymphoid or epithelial cells (NDX) on
cytology FNAB-TG levels ranged from < 0.15–22600 ng/
ml (median 0.3 ng/ml). Nineteen out of the 23 (83%)
NDX cases had TG levels < 10 ng/ml. Of the remaining 4
cases (17%) that had TG levels ≥ 10 ng/ml, three were
diagnosed as PTC on histology, and one had no follow-
up.
In the group of 14 cases diagnosed as atypical/suspicious
for PTC on cytology the FNAB-TG levels ranged from <
0.3–42560 ng/ml (median 14.9 ng/ml). Five of these
cases (36%) had TG levels < 10 ng/ml and were diagnosed
as PTC (n = 3) and PTC-TCV (n = 1) upon histological
examination. There was no follow-up available in one
case. Of the 9 cases (64%) with TG levels ≥ 10 ng/ml sur-
gical follow-up showed PTC (n = 6), PTC-TCV (n = 1), and
FVPTC (n = 2).
In the remaining three cases FNAB TG levels were: 2.8 ng/
ml in the case with the cytological diagnosis of paragang-
lioma, 1272 ng/ml in case diagnosed as poorly differenti-
ated carcinoma (PDCA) and 0.3 ng/ml in case diagnosed
as carcinoma not otherwise specified (Table 1).
Discussion
The well-differentiated thyroid carcinoma (WDTC) after
surgical excision and radioiodine ablation is usually fol-
lowed by basal and TSH stimulated serum TG measure-
ment, 131I whole body scan and neck ultrasound [20,21].
Since, well differentiated thyroid tumor cells retain their
functionality, elevated serum TG levels are often indica-
tive of residual tissue in thyroid bed or metastatic tumor
[22-24]. Tumor recurrences in WDTC are often encoun-
tered in thyroid bed, lateral and central neck nodes [23-
25]. The pathologic diagnosis of which is often required
before submitting the patient to further surgical explora-
tion because reactive/hyperplastic lymph nodes, reactive
scar tissue and rarely post-surgical traumatic neuroma can
mimic tumor recurrences on ultrasound examination
[11,14,16].
Ultrasound guided fine-needle aspiration biopsy (US-
FNAB) can effectively diagnose tumor recurrences in >
90% of cases on the basis of morphology alone, however,
false negative results can be seen in 6–8% of cases. This
could be due to absence of tumor cells in the FNAB spec-
imen, partial or focal involvement of the lymph node or
extensive tumor cell degeneration in some cases of PTC
[11-19,26]. Measurements of TG in the rinse of the aspira-
tion biopsy needle have been proposed for detection of
neck lymph node metastasis from WDTC in patients after
total thyroidectomy and radioiodine ablation [11-19,26].
Ultrasound image demonstrates a mixed cystic and solid  appearing lateral cervical lymph node in a patient with previ- ous thyroidectomy for papillary thyroid carcinoma Figure 1
Ultrasound image demonstrates a mixed cystic and solid 
appearing lateral cervical lymph node in a patient with previ-
ous thyroidectomy for papillary thyroid carcinoma.
Papanicolaou-stained fine-needle aspiration smear from a  lymph node showing metastatic papillary thyroid carcinoma Figure 2
Papanicolaou-stained fine-needle aspiration smear from a 
lymph node showing metastatic papillary thyroid carcinoma.CytoJournal 2008, 5:1 http://www.cytojournal.com/content/5/1/1
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Pacini et al in 1992 first reported the use of TG measure-
ments in FNAB specimens (FNAB-TG) of non-thyroidal
neck masses in 35 patients. In this study FNAB-TG levels
diagnosed metastatic thyroid cancer in 14 patients, which
was confirmed by histopathologic follow-up. These
authors concluded that FNAB-TG had better negative pre-
dictive value than cytology alone [11]. Cignarelli et al
reported FNA-TG to be more sensitive than FNAB alone
especially in cases where cystic degeneration of metastatic
deposits in neck nodes may contain few degenerated or
no tumor cells [15]. Similar results have been docu-
mented by various studies from other insititutions [12-
14,16-19,26].
In the present study we analyze the usefulness of TG levels
as an adjuvant to FNAB in the diagnosis of lymph nodes
suspicious for recurrence of PTC under ultrasound in 115
cases in 89 patients with history of previous thyroid carci-
noma. When analyzing our results some discrepancies
between the cytological diagnosis and the expected TG
level were noted. Of the eleven cases (11/39 28%) diag-
nosed as PTC and 4 cases (4/15 27%) diagnosed as atypi-
cal/suspicious for PTC on cytology with TG levels < 10 ng/
ml, eight cases (8/15 53%) had a diagnosis of PTC-TCV on
histologic follow-up. The PTC-TCV is an aggressive variant
of PTC. Its pathologic diagnosis is dependent upon the
characteristic morphology i.e. presence of elongated cells
with height being three times the width, oncocytic cyto-
plasm and nuclear features of PTC. It has been shown that
these tumors can be difficult to treat because of their loss
of iodine-avidity and decreased or absence of thyroglobu-
lin production; this is especially encountered in recurrent
tumors [26].
The limitations of FNAB, particularly in the setting of
cystic lymph nodes where sampling of diagnostic areas is
potentially problematic, were highlighted by the correla-
tion with TG levels. All of the 5 cases diagnosed as no
tumor seen on cytology with TG levels ≥ 10 ng/ml resulted
in PTC on surgical follow-up. Similarly, 3 cases consid-
ered non-diagnostic on cytology due to lack of any cells
with increased TG levels resulted in PTC diagnoses on fol-
low-up.
Particularly important are the results in the category of
atypical/suspicious for PTC recurrence. The cases with TG
levels ≥ 10 ng/ml resulted in the diagnoses of PTC on fol-
low-up; however, all cases with TG levels within normal
limits also resulted in diagnosis of malignancy. This led us
to believe that the cytopathology findings should rule
over TG levels especially in cases of atypical/suspicious
cytologic results. TG levels will not aid in the distinction
between benign and malignant if a cytological specimen
is atypical enough to warrant this diagnosis.
The diagnostic value of FNAB and FNAB-TG could not be
calculated in this study due to lack of histologic follow-up
in majority of cases diagnosed as no tumor seen and non-
diagnostic.
The presence of serum anti-TG antibodies (TG-Ab) which
can occur in up to 25–30% of patients can seriously affect
serum TG measurements leading to either false positive or
false negative results [27,28]. Therefore some authors
have excluded patients with serum TG-Ab from their stud-
ies on the role of TG-FNAB in the diagnosis of recurrent
WDTC [14]. Recently reports by Baskin et al and Boi et al
have shown that TG-FNAB measurements are not affected
significantly by the presence of TG-Ab in the FNAB speci-
men [16,18]. In view of these studies we did not include
the presence or absence of TG-Ab in this study.
In summary, we have demonstrated similar to other stud-
ies that TG can be effectively measured in FNAB speci-
Table 1: Summary of FNAB diagnoses with histological follow-up and FNAB-TG levels correlation
SURGICAL PATHOLOGY FOLLOW-UP
TG Levels ≥ 10 ng/ml TG Levels ≤ 10 ng/ml
Cytologic-DX
PTC Other CA No F/U PTC Other CA No F/U
PTC (n = 39) 25 0 3 10* 1** 0
NTS (n = 35) 50 0 00 3 0
NDX(n = 23) 30 1 00 1 9
ATYP (n = 15) 90 0 4 * 0 1
OTHER (n = 3) 01 * * * 0 01 * * * * 0
DX = Diagnosis, TG = Thyroglobulin, F/U = surgical pathology follow- up, PTC = Papillary thyroid carcinoma, CA = Carcinoma, NTS = No tumor 
seen, NDX = Non-diagnostic, ATYP = Atypical/Suspicious, * = includes cases of tall cell variant of papillary carcinoma, ** = metastatic well-
differentiated follicular derived carcinoma *** = poorly differentiated carcinoma, **** = carcinoma not otherwise specified.Publish with BioMed Central    and   every 
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mens from lymph nodes. FNAB-TG measurement is a
useful technique for the diagnosis of lymph node metas-
tasis originating from well-differentiated thyroid carci-
noma, particularly when confronted with abnormal-
appearing lymph nodes of small size or that have under-
gone cystic change.
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